anticoagulants

Summary

Summary: Agents that prevent blood clotting. Naturally occurring agents in the blood are included only when they are used as drugs.

Top Publications

  1. ncbi Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
    Manesh R Patel
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    N Engl J Med 365:883-91. 2011
  2. ncbi Dabigatran versus warfarin in patients with atrial fibrillation
    Stuart J Connolly
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 361:1139-51. 2009
  3. ncbi Apixaban versus warfarin in patients with atrial fibrillation
    Christopher B Granger
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    N Engl J Med 365:981-92. 2011
  4. ncbi Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation
    Robert G Hart
    Department of Medicine Neurology, University of Texas Health Science Center, San Antonio, Texas 78229 3900, USA
    Ann Intern Med 146:857-67. 2007
  5. ncbi Underuse of oral anticoagulants in atrial fibrillation: a systematic review
    Isla M Ogilvie
    BioMedCom Consultants Inc, Montreal, QC, Canada
    Am J Med 123:638-645.e4. 2010
  6. ncbi Rivaroxaban in patients with a recent acute coronary syndrome
    Jessica L Mega
    Thrombolysis in Myocardial Infarction Study Group, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 366:9-19. 2012
  7. pmc The net clinical benefit of warfarin anticoagulation in atrial fibrillation
    Daniel E Singer
    Massachusetts General Hospital, Boston, Massachussetts 02114, USA
    Ann Intern Med 151:297-305. 2009
  8. ncbi Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects
    Elise S Eerenberg
    Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands
    Circulation 124:1573-9. 2011
  9. pmc Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    John J You
    Department of Medicine, McMaster University, Hamilton, ON, Canada
    Chest 141:e531S-75S. 2012
  10. ncbi Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Daniel E Singer
    Clinical Epidemiology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Chest 133:546S-592S. 2008

Detail Information

Publications385 found, 100 shown here

  1. ncbi Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
    Manesh R Patel
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    N Engl J Med 365:883-91. 2011
    ..Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent and predictable anticoagulation than warfarin...
  2. ncbi Dabigatran versus warfarin in patients with atrial fibrillation
    Stuart J Connolly
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 361:1139-51. 2009
    ..Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor...
  3. ncbi Apixaban versus warfarin in patients with atrial fibrillation
    Christopher B Granger
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    N Engl J Med 365:981-92. 2011
    ..Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a similar population in comparison with aspirin...
  4. ncbi Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation
    Robert G Hart
    Department of Medicine Neurology, University of Texas Health Science Center, San Antonio, Texas 78229 3900, USA
    Ann Intern Med 146:857-67. 2007
    ..Atrial fibrillation is a strong independent risk factor for stroke...
  5. ncbi Underuse of oral anticoagulants in atrial fibrillation: a systematic review
    Isla M Ogilvie
    BioMedCom Consultants Inc, Montreal, QC, Canada
    Am J Med 123:638-645.e4. 2010
    ..This systematic review compares current treatment practices for stroke prevention in atrial fibrillation with published guidelines...
  6. ncbi Rivaroxaban in patients with a recent acute coronary syndrome
    Jessica L Mega
    Thrombolysis in Myocardial Infarction Study Group, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 366:9-19. 2012
    ..Since factor Xa plays a central role in thrombosis, the inhibition of factor Xa with low-dose rivaroxaban might improve cardiovascular outcomes in patients with a recent acute coronary syndrome...
  7. pmc The net clinical benefit of warfarin anticoagulation in atrial fibrillation
    Daniel E Singer
    Massachusetts General Hospital, Boston, Massachussetts 02114, USA
    Ann Intern Med 151:297-305. 2009
    ..These guidelines rely on ischemic stroke rates observed in older trials and do not explicitly account for increased risk for hemorrhage...
  8. ncbi Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects
    Elise S Eerenberg
    Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands
    Circulation 124:1573-9. 2011
    Rivaroxaban and dabigatran are new oral anticoagulants that specifically inhibit factor Xa and thrombin, respectively. Clinical studies on the prevention and treatment of venous and arterial thromboembolism show promising results...
  9. pmc Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    John J You
    Department of Medicine, McMaster University, Hamilton, ON, Canada
    Chest 141:e531S-75S. 2012
    ..We provide recommendations for antithrombotic treatment based on net clinical benefit for patients with AF at varying levels of stroke risk and in a number of common clinical scenarios...
  10. ncbi Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Daniel E Singer
    Clinical Epidemiology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Chest 133:546S-592S. 2008
    ..However, in patients without contraindications to anticoagulation, we suggest beginning IV heparin or LMWH at presentation (Grade 2C)...
  11. ncbi Pulmonary embolism and deep vein thrombosis
    Samuel Z Goldhaber
    Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, Cardiovascular Division, Boston, MA 02115, USA
    Lancet 379:1835-46. 2012
    ..In this Seminar, we discuss pulmonary embolism and deep vein thrombosis of the legs...
  12. ncbi Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
    S Schulman
    Coagulation Unit, Karolinska University Hospital, Stockholm, Sweden
    J Thromb Haemost 3:692-4. 2005
    ..was developed that should be applicable to studies with all agents that interfere with hemostasis, including anticoagulants, platelet function inhibitors and fibrinolytic drugs...
  13. ncbi Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial
    S Connolly
    Health Research Institute, Hamilton, ON, Canada
    Lancet 367:1903-12. 2006
    ..However, long-term monitoring is necessary and many patients cannot achieve optimum anticoagulation. We assessed whether clopidogrel plus aspirin was non-inferior to oral anticoagulation therapy for prevention of vascular events...
  14. ncbi Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial
    John W Eikelboom
    Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada
    Circulation 123:2363-72. 2011
    ..The purpose of this study was to compare their risks of bleeding in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial...
  15. ncbi Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation
    James V Freeman
    Stanford University School of Medicine, California, USA
    Ann Intern Med 154:1-11. 2011
    ..Dabigatran is a fixed-dose, oral direct thrombin inhibitor with similar or reduced rates of ischemic stroke and intracranial hemorrhage in patients with AF compared with those of warfarin...
  16. ncbi A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation
    Isabelle C Van Gelder
    Department of Cardiology, Thoraxcenter, University Hospital, Groningen, The Netherlands
    N Engl J Med 347:1834-40. 2002
    ..We hypothesized that ventricular rate control is not inferior to the maintenance of sinus rhythm for the treatment of atrial fibrillation...
  17. ncbi Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study
    Leif Friberg
    Department of Cardiology, Karolinska Instituet, Danderyd University Hospital, Stockholm, Sweden
    Eur Heart J 33:1500-10. 2012
    ..Our objective was to investigate risk factors for stroke and bleeding in AF, and application of the new CHA(2)DS(2)-VASc and HAS-BLED schemes for stroke and bleeding risk assessments, respectively...
  18. ncbi Dabigatran versus warfarin in the treatment of acute venous thromboembolism
    Sam Schulman
    Department of Medicine, McMaster University and Henderson Research Centre, Hamilton, ON, Canada
    N Engl J Med 361:2342-52. 2009
    ..The direct oral thrombin inhibitor dabigatran has a predictable anticoagulant effect and may be an alternative therapy to warfarin for patients who have acute venous thromboembolism...
  19. ncbi Fucoidan: structure and bioactivity
    Bo Li
    School of Food Science, Henan Institute of Science and Technology, Xinxiang 453003, Henan, P R China
    Molecules 13:1671-95. 2008
    ..This review summarizes the research progress on the structure and bioactivity of fucoidan and the relationships between structure and bioactivity...
  20. ncbi Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity
    Joanne van Ryn
    Department of Drug Discovery Support, Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany
    Thromb Haemost 103:1116-27. 2010
    ....
  21. ncbi Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study
    Alexander T Cohen
    King s College Hospital, London, UK
    Lancet 371:387-94. 2008
    ....
  22. ncbi Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty
    Bengt I Eriksson
    Sahlgrenska University Hospital Ostra, Gothenburg, Sweden
    N Engl J Med 358:2765-75. 2008
    ..This phase 3 trial compared the efficacy and safety of rivaroxaban, an oral direct inhibitor of factor Xa, with those of enoxaparin for extended thromboprophylaxis in patients undergoing total hip arthroplasty...
  23. ncbi The use of dabigatran immediately after atrial fibrillation ablation
    Roger A Winkle
    Cardiovascular Medicine and Cardiac Arrhythmias, E Palo Alto, Sequoia Hospital, Redwood City, California, USA
    J Cardiovasc Electrophysiol 23:264-8. 2012
    ..Dabigatran is a new anticoagulant and may be useful after AF ablation to prevent thromboembolic events...
  24. ncbi How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch
    Sam Schulman
    Department of Medicine, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada
    Blood 119:3016-23. 2012
    Two novel oral anticoagulants, dabigatran and rivaroxaban, have recently been approved...
  25. ncbi Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation
    Soyon Lee
    University of Connecticut School of Pharmacy, Storrs, CT, USA
    Am J Cardiol 110:845-51. 2012
    ..In conclusion, this Markov model suggests that rivaroxaban therapy may be a cost-effective alternative to adjusted-dose warfarin for stroke prevention in AF...
  26. ncbi Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial
    Robert G Hart
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada
    Stroke 43:1511-7. 2012
    ..Intracranial hemorrhage is the most devastating complication of anticoagulation. Outcomes associated with different sites of intracranial bleeding occurring with warfarin versus dabigatran have not been defined...
  27. ncbi Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drug
    Gregory Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, England
    J Am Coll Cardiol 57:173-80. 2011
    ..The purpose of this study was to investigate predictors of bleeding in a cohort of anticoagulated patients and to evaluate the predictive value of several bleeding risk stratification schemas...
  28. ncbi Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA
    Mattias Wieloch
    Department of Clinical Sciences, Malmo, Lund University, Sweden
    Eur Heart J 32:2282-9. 2011
    ..This is the first report of TTR in AuriculA and, in a subgroup of two centres, bleeding and thrombo-embolic complications during 2008...
  29. ncbi Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty
    Michael R Lassen
    Nordsjaellands Hospital, Hørsholm, Denmark
    N Engl J Med 358:2776-86. 2008
    ..We investigated the efficacy of rivaroxaban, an orally active direct factor Xa inhibitor, in preventing venous thrombosis after total knee arthroplasty...
  30. ncbi Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    William H Geerts
    Thromboembolism Program, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada
    Chest 133:381S-453S. 2008
    ..We recommend that, on admission to the ICU, all patients be assessed for their risk of VTE, and that most receive thromboprophylaxis (Grade 1A)...
  31. pmc Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care
    S DeWilde
    Division of Community Health Sciences, St George s, University of London, Cranmer Terrace, London SW17 0RE, UK
    Heart 92:1064-70. 2006
    To examine trends in the prevalence of diagnosed atrial fibrillation (AF), its treatment with oral anticoagulants between 1994 and 2003, and predictors of anticoagulant treatment in 2003.
  32. ncbi Apixaban versus enoxaparin for thromboprophylaxis after hip replacement
    Michael Rud Lassen
    Department of Orthopedics, Spine Clinic, and Clinical Trial Unit, Hørsholm Hospital, University of Copenhagen, Hørsholm, Denmark
    N Engl J Med 363:2487-98. 2010
    ..Orally active, specific factor Xa inhibitors such as apixaban may provide effective thromboprophylaxis with a lower risk of bleeding and improved ease of use...
  33. pmc Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing
    J A Johnson
    Department of Pharmacotherapy and Translational Research, College of Pharmacy, and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA
    Clin Pharmacol Ther 90:625-9. 2011
    ..pharmgkb.org based on new developments in the field.(1)...
  34. ncbi Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial
    Lars Wallentin
    Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden
    Lancet 376:975-83. 2010
    ..We aimed to investigate the primary and secondary outcomes of the RE-LY trial in relation to each centre's mean TTR (cTTR) in the warfarin population...
  35. ncbi Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate
    Joachim Stangier
    Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany
    Clin Pharmacokinet 47:285-95. 2008
    ....
  36. ncbi Rivaroxaban for thromboprophylaxis in acutely ill medical patients
    Alexander T Cohen
    Department of Vascular Surgery, King s College Hospital, London SE5 9RS, United Kingdom
    N Engl J Med 368:513-23. 2013
    ....
  37. ncbi European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation
    Hein Heidbuchel
    Department of Cardiovascular Medicine, University Hospital Gasthuisberg, University of Leuven, Leuven, Belgium
    Europace 15:625-51. 2013
    New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with non-valvular atrial fibrillation (AF)...
  38. ncbi Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial
    Alexander G G Turpie
    McMaster University, Hamilton, Ontario L8L 2X2, Canada
    Lancet 373:1673-80. 2009
    ..We aimed to test the efficacy and safety of oral rivaroxaban for the prevention of venous thromboembolism after total knee arthroplasty...
  39. ncbi Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry
    Dhanunjaya Lakkireddy
    Division of Cardiovascular Diseases, Cardiovascular Research Institute, Mid America Cardiology, University of Kansas Hospital and Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160 7200, USA
    J Am Coll Cardiol 59:1168-74. 2012
    ..The purpose of this study was to evaluate the feasibility and safety of periprocedural dabigatran during atrial fibrillation (AF) ablation...
  40. pmc Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record
    Andrea H Ramirez
    Department of Medicine, Vanderbilt University in Nashville, TN 37232, USA
    Pharmacogenomics 13:407-18. 2012
    ..Electronic health record (EHR) systems linked to biobanks may allow for pharmacogenomic analysis, but they have not yet been used for this purpose...
  41. ncbi Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data
    Carl Heneghan
    Oxford University, Department of Primary Care Health Sciences, Oxford, UK
    Lancet 379:322-34. 2012
    ....
  42. ncbi Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients
    Samuel Z Goldhaber
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 365:2167-77. 2011
    ..We hypothesized that extended prophylaxis with apixaban would be safe and more effective than short-term prophylaxis with enoxaparin...
  43. pmc Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    Walter Ageno
    University of Insubria, Varese, Italy
    Chest 141:e44S-88S. 2012
    ....
  44. ncbi Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial
    Stefan H Hohnloser
    Division of Clinical Electrophysiology, J W Goethe University Hospital, Theodor Stern Kai 7, Frankfurt, Germany
    Circulation 125:669-76. 2012
    ..There is a modest risk of myocardial infarction (MI) and myocardial ischemic events in patients with atrial fibrillation...
  45. ncbi Serpin-independent anticoagulant activity of a fucosylated chondroitin sulfate
    Bianca F Glauser
    Laboratório de Tecido Conjuntivo, Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Cidade Universitaria, Ilha do Fundao, Caixa Postal 68041, Rio de Janeiro, RJ, 21941 590, Brazil
    Thromb Haemost 100:420-8. 2008
    ..In plasma systems, the serpin-independent anticoagulant effect of fucosylated chondroitin sulfate predominates over its serpin-dependent action. This glycosaminoglycan opens new avenues for the development of antithrombotic agents...
  46. ncbi Systematic overview of warfarin and its drug and food interactions
    Anne M Holbrook
    Centre for Evaluation of Medicines, St Joseph s Healthcare, Hamilton, Ontario
    Arch Intern Med 165:1095-106. 2005
    ..Drug and food interactions are frequently cited as causes of adverse events with warfarin. We provide an updated systematic overview of the quality, clinical effect, and importance of these reported interactions...
  47. ncbi Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality
    Alexander T Cohen
    Vascular Medicine, Department of Surgery, King s College Hospital, London, SE5 9RS, UK
    Thromb Haemost 98:756-64. 2007
    ..Given the availability of effective VTE prophylaxis, many of these events and deaths could have been prevented. These results have important implications for the allocation of healthcare resources...
  48. ncbi Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range
    Stuart J Connolly
    Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
    Circulation 118:2029-37. 2008
    ..This report examines how differences in time in therapeutic range (TTR) between centers and between countries affect the outcomes of OAC therapy...
  49. ncbi Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation
    Daniela Poli
    Thrombosis Centre Department of Heart and Vessels, AOU Careggi, Florence, Italy
    Circulation 124:824-9. 2011
    ..We performed a large multicenter prospective observational study that enrolled very old patients to evaluate the quality of anticoagulation and the incidence of bleedings...
  50. ncbi Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion
    Rangadham Nagarakanti
    Louisiana State University School of Medicine, New Orleans, LA, USA
    Circulation 123:131-6. 2011
    ..The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial compared dabigatran 110 mg BID (D110) and 150 mg BID (D150) with warfarin for stroke prevention in 18 113 patients with nonvalvular atrial fibrillation...
  51. ncbi Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Jack Ansell
    Department of Medicine, Boston University Medical Center, 88 East Newton Street, Boston, MA 02118, USA
    Chest 133:160S-198S. 2008
    ..Patient self-monitoring or self-management, however, is a choice made by patients and physicians that depends on many factors. We suggest that such therapeutic management be implemented where suitable (Grade 2B)...
  52. ncbi Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system
    Theodore Darkow
    Health Informatics and Outcomes Research Division, Prescription Solutions, Costa Mesa, CA 92626, USA
    Curr Med Res Opin 21:1583-94. 2005
    ....
  53. ncbi Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial
    Bengt I Eriksson
    Department of Orthopaedic Surgery, Sahlgrenska University Hospital Ostra, Gothenburg, Sweden
    Lancet 370:949-56. 2007
    ..After hip replacement surgery, prophylaxis following discharge from hospital is recommended to reduce the risk of venous thromboembolism. Our aim was to assess the oral, direct thrombin inhibitor dabigatran etexilate for such prophylaxis...
  54. ncbi Biological activities of sulfated polysaccharides from tropical seaweeds
    L S Costa
    UFRN, Laboratório de Biotecnologia de Polímeros Naturais Biopol, Centro de Biociencias, Departamento de Bioquimica, Universidade Federal do Rio Grande do Norte, Av Sen Salgado Filho, 3000, 59072970 Natal, Rio Grande do Norte, Brazil
    Biomed Pharmacother 64:21-8. 2010
    ....
  55. ncbi Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran
    Michael D Ezekowitz
    Lankenau Institute for Medical Research and The Heart Center, Wynnewood, PA, USA
    Am Heart J 157:805-10, 810.e1-2. 2009
    ..The worldwide site distribution and broad range of stroke risk further increase the general applicability of the trial. Results are expected in 2009...
  56. ncbi Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis
    Simon McRae
    Department of Haematology and Oncology, Queen Elizabeth Hospital, Woodville, Australia
    Lancet 368:371-8. 2006
    ..We did a meta-analysis to assess from available evidence whether men and women have the same risk of recurrent venous thromboembolism after stopping anticoagulant treatment...
  57. ncbi Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study
    Jorg Carlsson
    Department of Internal Medicine II, Klinikum Lippe Detmold, Röntgenstrasse 18, D 32760 Detmold, Germany
    J Am Coll Cardiol 41:1690-6. 2003
    ....
  58. ncbi Heterofucans from Dictyota menstrualis have anticoagulant activity
    I R L Albuquerque
    Laboratório de Biotecnologia de Polímeros Naturais, Departamento de Bioquimica, Universidade Federal do Rio Grande do Norte, 59072 970 Natal, RN, Brazil
    Braz J Med Biol Res 37:167-71. 2004
    ..0:0.8:0.7:0.8:0.4 and 1.0:0.3:0.4:1.5:1.3, respectively. This is the fist report indicating the presence of a heterofucan with higher anticoagulant activity from brown seaweed...
  59. ncbi Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation
    Elaine M Hylek
    General Medicine Division, Clinical Epidemiology Unit, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    N Engl J Med 349:1019-26. 2003
    ..0 or greater. The effect of the intensity of oral anticoagulation on the severity of atrial fibrillation-related stroke is not known but is central to the choice of the target INR...
  60. ncbi Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery
    Jeffrey S Ginsberg
    McMaster University Medical Centre, Ontario, Canada
    J Arthroplasty 24:1-9. 2009
    ..Dabigatran, effective compared to once-daily enoxaparin, showed inferior efficacy to the twice-daily North American enoxaparin regimen, probably because of the latter's more intense and prolonged dosing...
  61. ncbi Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study
    A S Go
    Kaiser Permanente Medical Care Program Northern California, Oakland 94611 5714, USA
    Ann Intern Med 131:927-34. 1999
    ..Warfarin dramatically reduces the risk for ischemic stroke in nonvalvular atrial fibrillation, but its use among ambulatory patients with atrial fibrillation has not been widely studied...
  62. ncbi Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation
    Jeffrey L Anderson
    Cardiovascular Department, LDS Hospital, Intermountain Healthcare, Salt Lake City, UT, USA
    Circulation 116:2563-70. 2007
    ..Pharmacogenetic-guided dosing of warfarin is a promising application of "personalized medicine" but has not been adequately tested in randomized trials...
  63. pmc Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups
    Nita A Limdi
    University of Alabama at Birmingham, USA
    Blood 115:3827-34. 2010
    ..Thus, clinicians should recognize that, although at a population level, the contribution of VKORC1 toward dose requirements is higher in whites than in nonwhites; genotype predicts similar dose requirements across racial groups...
  64. pmc Effect of anticoagulants on multiplexed measurement of cytokine/chemokines in healthy subjects
    Angelique Biancotto
    Center for Human Immunology, Autoimmunity, and Inflammation, National Institutes of Health, Bethesda, MD 28092, USA
    Cytokine 60:438-46. 2012
    ..characteristics of 72 analytes measured by multiplex cytokine immunoassay, with an emphasis on the differences of analytes measured in serum compared to plasma, and, in plasma, on the impact of anticoagulants on the cytokine measurement.
  65. pmc Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
    B F Gage
    Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri, USA
    Clin Pharmacol Ther 84:326-31. 2008
    ..To facilitate use of these pharmacogenetic and clinical algorithms, we developed a nonprofit website, http://www.WarfarinDosing.org...
  66. ncbi Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing continuous renal replacement therapy
    Zhongheng Zhang
    Department of Critical Care Medicine, Jinhua Central Hospital, 351 Mingyue Road, Jinhua 321000, Zhejiang, China
    Intensive Care Med 38:20-8. 2012
    ..In recent years, several randomized controlled trials have been conducted to investigate its superiority over other anticoagulation modes. Thus, we performed a systematic review of available evidence on the efficacy and safety of RCA...
  67. ncbi New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper
    Raffaele De Caterina
    G D Annunzio University, Chieti, Italy
    J Am Coll Cardiol 59:1413-25. 2012
    Until recently, vitamin K antagonists were the only available oral anticoagulants, but with numerous limitations that prompted the introduction of new oral anticoagulants targeting the single coagulation enzymes thrombin (dabigatran) or ..
  68. ncbi Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial
    Gregory W Albers
    Stanford Stroke Center, Palo Alto, Calif, USA
    JAMA 293:690-8. 2005
    ..In patients with nonvalvular atrial fibrillation, warfarin prevents ischemic stroke, but dose adjustment, coagulation monitoring, and bleeding limit its use...
  69. pmc Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    Lori Ann Linkins
    Department of Medicine, McMaster University, Juravinski Hospital, Rm M0118, 1280 Main St W, Hamilton, ON, L8S 4K1, Canada
    Chest 141:e495S-530S. 2012
    ....
  70. ncbi An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation
    Simon Mantha
    Department of Hematology, Lahey Clinic, Burlington, MA 01805, USA
    Thromb Haemost 108:476-84. 2012
    ..Such an indirect comparison should be used only to generate hypotheses which need to be tested in a dedicated randomised trial comparing the three drugs directly...
  71. ncbi Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation
    Gregory Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
    J Am Coll Cardiol 60:738-46. 2012
    ..This study sought to perform an indirect comparison analysis of dabigatran etexilate (2 doses), rivaroxaban, and apixaban for their relative efficacy and safety against each other...
  72. ncbi Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature
    Francesco Dentali
    Department of Clinical and Experimental Medicine, Insubria University, Varese, Italy
    Circulation 126:2381-91. 2012
    Novel oral anticoagulants (NOACs) have been proposed as alternatives to vitamin K antagonists for the prevention of stroke and systemic embolism in patients with atrial fibrillation...
  73. ncbi Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
    Christian T Ruff
    Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA Electronic address
    Lancet 383:955-62. 2014
    Four new oral anticoagulants compare favourably with warfarin for stroke prevention in patients with atrial fibrillation; however, the balance between efficacy and safety in subgroups needs better definition...
  74. ncbi Drug and dietary interactions of warfarin and novel oral anticoagulants: an update
    Edith Nutescu
    Department of Pharmacy Practice and Center for Pharmacoeconomic Research, University of Illinois at Chicago, College of Pharmacy, 833 S Wood St MC 886, Rm 164, Chicago, IL 60612, USA
    J Thromb Thrombolysis 31:326-43. 2011
    ..extensive food and drug interactions, there is also a need to consider such interactions with the new oral anticoagulants. While to date few drug and dietary interactions have been reported with the new oral anticoagulants, it is ..
  75. ncbi Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism
    Bengt I Eriksson
    Department of Orthopaedics, Sahlgrenska University Hospital, Molndal, Sweden
    Annu Rev Med 62:41-57. 2011
    The last decade has seen the evaluation of several new oral anticoagulants that directly target thrombin or activated factor X (FXa)...
  76. ncbi Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial
    Antonio L Dans
    College of Medicine, University of the Philippines Manila, Ermita, Manila, Philippines 1000
    Circulation 127:634-40. 2013
    ..In this subgroup analysis, we assess the efficacy and safety of dabigatran in patients who did and did not receive concomitant antiplatelets...
  77. pmc The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
    Joachim Stangier
    Boehringer Ingelheim Pharma GmbH and Co KG, Ingelheim, Germany
    Br J Clin Pharmacol 64:292-303. 2007
    ..Two double-blind, randomized trials were undertaken to investigate the pharmacokinetics (PK), pharmacodynamics (PD) and tolerability of orally administered dabigatran etexilate in healthy male subjects...
  78. ncbi Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation
    Shimoli V Shah
    Department of Medicine, Washington University School of Medicine, Campus Box 8005, 660 S Euclid Ave, St Louis, MO 63110, USA
    Circulation 123:2562-70. 2011
    ..Recent studies have investigated alternatives to warfarin for stroke prophylaxis in patients with atrial fibrillation (AF), but whether these alternatives are cost-effective is unknown...
  79. ncbi Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation
    Albert L Waldo
    Division of Cardiology, Case Western University University Hospitals of Cleveland, Cleveland, Ohio 44106 5038, USA
    J Am Coll Cardiol 46:1729-36. 2005
    ..The purpose of this study was to determine both treatment gaps and predictors of warfarin use in atrial fibrillation (AF) patients enrolled in a national multicenter study...
  80. ncbi Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis
    Shikhar Agarwal
    Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Ohio, USA
    Arch Intern Med 172:623-31; discussion 631-3. 2012
    ..We performed a meta-analysis of safety and efficacy outcomes in patients with AF treated with warfarin for stroke prevention in large contemporary randomized controlled trials (RCTs)...
  81. ncbi Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack
    Hooman Kamel
    Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, NY, USA
    Stroke 43:881-3. 2012
    ..The cost-effectiveness of dabigatran for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack has not been directly assessed...
  82. ncbi Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial
    Jonas Oldgren
    Uppsala Clinical Research Centre and Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Ann Intern Med 155:660-7, W204. 2011
    ..validated risk score for predicting the risk for stroke in patients with atrial fibrillation not treated with anticoagulants. There are sparse data on the risk for thrombotic and bleeding complications according to the CHADS(2) score ..
  83. ncbi Effect of study setting on anticoagulation control: a systematic review and metaregression
    Carl van Walraven
    Clinical Epidemiology Program, Ottawa Health Research Institute, C405, Ottawa Hospital, Civic Campus, 1053 Carling Ave, Ottawa, ON, K1Y 4E9 Canada
    Chest 129:1155-66. 2006
    For patients receiving therapy with oral anticoagulants (OACs), the proportion of time spent in the therapeutic range (ie, anticoagulation control) is strongly associated with bleeding and thromboembolic risk...
  84. ncbi Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience
    Jai Wun Park
    Department of Cardiology, Asklepios Klinik Harburg, Hamburg, Germany
    Catheter Cardiovasc Interv 77:700-6. 2011
    ..This study details the initial experience with the Amplatzer Cardiac Plug (ACP) in humans...
  85. ncbi Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation
    Corey S Miller
    Division of Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
    Am J Cardiol 110:453-60. 2012
    New oral anticoagulants, including apixaban, dabigatran, and rivaroxaban, have been developed as alternatives to warfarin, the standard oral anticoagulation therapy for patients with atrial fibrillation (AF)...
  86. ncbi Apixaban or enoxaparin for thromboprophylaxis after knee replacement
    Michael Rud Lassen
    Department of Orthopedics, Spine Clinic, Clinical Trial Unit, Hørsholm Hospital, University of Copenhagen, Hørsholm, Denmark
    N Engl J Med 361:594-604. 2009
    ..Apixaban, a specific factor Xa inhibitor, may provide effective thromboprophylaxis with a low risk of bleeding and improved ease of use...
  87. ncbi Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis
    Patrick Andre
    Millennium Pharmaceuticals, Inc, 256 E Grand Ave, South San Francisco, Calif 9408, USA
    Circulation 108:2697-703. 2003
    This study was designed to determine whether (1) P2Y12 antagonism synergizes with other antithrombotics and (2) anticoagulants (thrombin inhibitors) affect the antithrombotic activity elicited by P2Y12 antagonism.
  88. ncbi Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control
    Christopher Ll Morgan
    Cardiff Research Consortium Ltd, University Hospital of Wales, Heath Park, Cardiff CF14 4UJ, UK
    Thromb Res 124:37-41. 2009
    ..We aimed to determine the level of INR control associated with reduced stroke and mortality...
  89. ncbi Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)
    Adam Torbicki
    Department of Chest Medicine, Institute for Tuberculosis and Lung Diseases, Warsaw, Poland
    Eur Heart J 29:2276-315. 2008
    ..With the exception of severe air and fat embolism, the haemodynamic consequences of non-thrombotic emboli are usually mild. Treatment is mostly supportive but may differ according to the type of embolic material and clinical severity...
  90. ncbi A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin
    Giovanna D'Andrea
    Unita di Aterosclerosi e Trombosi, Istituto di Ricovero e Cura a Carattere Scientifico, S Giovanni Rotondo, Foggia, Italy
    Blood 105:645-9. 2005
    ..353) of the interindividual variability. Genetic variants of the VKORC1 gene locus modulate the mean daily dose of drug prescribed to acquire the target anticoagulation intensity...
  91. pmc Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses
    Joshua Pink
    Centre for Health Economics and Medicines Evaluation, Institute of Medical and Social Care Research, Bangor University, Bangor, Gwynedd LL57 1UT, UK
    BMJ 343:d6333. 2011
    ....
  92. ncbi The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen
    Elizabeth A Sconce
    School of Clinical and Laboratory Sciences, University of Newcastle, Newcastle upon Tyne, United Kingdom
    Blood 106:2329-33. 2005
    ..Based upon the data, a new warfarin dosing regimen has been developed. The validity of the dosing regimen was confirmed in a second cohort of patients on warfarin therapy...
  93. ncbi The increasing incidence of anticoagulant-associated intracerebral hemorrhage
    M L Flaherty
    Department of Neurology, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0525, USA
    Neurology 68:116-21. 2007
    ..To define temporal trends in the incidence of anticoagulant-associated intracerebral hemorrhage (AAICH) during the 1990s and relate them to rates of cardioembolic ischemic stroke...
  94. ncbi The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage
    Jonathan Rosand
    Neurology Clinical Trials Unit, Department of Neurology, Massachusetts General Hospital, 15 Parkman Street, Boston, MA 02114, USA
    Arch Intern Med 164:880-4. 2004
    ..We studied the determinants of ICH outcome to quantify the independent effect of warfarin...
  95. pmc Triggers, targets and treatments for thrombosis
    Nigel Mackman
    Division of Hematology Oncology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Nature 451:914-8. 2008
    ..The pathogenic changes that occur in the blood vessel wall and in the blood itself resulting in thrombosis are not fully understood. Understanding these processes is crucial for developing safer and more effective antithrombotic drugs...
  96. ncbi Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial
    Bengt I Eriksson
    University of Gothenburg, Department of Orthopaedics, Sahlgrenska University Hospital, Molndal, Sweden
    Thromb Haemost 105:721-9. 2011
    ..The risk of bleeding and safety profiles were similar...
  97. ncbi Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infar
    Christian T Ruff
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Am Heart J 160:635-41. 2010
    ..Edoxaban is a selective and direct factor Xa inhibitor that may provide effective, safe, and more convenient anticoagulation...
  98. ncbi Selective cleavage and anticoagulant activity of a sulfated fucan: stereospecific removal of a 2-sulfate ester from the polysaccharide by mild acid hydrolysis, preparation of oligosaccharides, and heparin cofactor II-dependent anticoagulant activity
    Vitor H Pomin
    Laboratório de Tecido Conjuntivo, Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Caixa Postal 68041, Rio de Janeiro, RJ, 21941 590, Brazil
    Glycobiology 15:369-81. 2005
    ..We speculate that the template mechanism may predominate over the allosteric effect in the case of the linear sulfated fucan inactivation of thrombin in the presence of heparin cofactor II...
  99. ncbi Potential antioxidant and anticoagulant capacity of low molecular weight fucoidan fractions extracted from Laminaria japonica
    Jing Wang
    Institute of Oceanology, Chinese Academy of Sciences, Qingdao 266071, PR China
    Int J Biol Macromol 46:6-12. 2010
    ..Available data presented the content of sulfate group, the molar ratio of sulfate/fucose and sulfate/total sugar, and the molecular weight played an important role on antioxidant and anticoagulant activity...
  100. ncbi Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 159:331-9. 2010
    ....

Research Grants64

  1. Dual Direct Inhibitors of Thrombin and Factor Xa
    UMESH RAMANLAL DESAI; Fiscal Year: 2012
    ..Even more alarming is that thrombotic disorders are ~3-fold more likely in people with cancer. Anticoagulants, including heparins and coumarins, are the mainstay of treatment and prevention of thromboembolic disorders...
  2. Effectiveness and Safety of Antithrombotic Strategies after Joint Replacement
    Elaine Hylek; Fiscal Year: 2013
    ..Further heightening the uncertainty, higher all-cause mortality has been reported with use of potent anticoagulants and a pooled analysis of VTE prevention trials reported a 7-fold higher risk of death among patients who ..
  3. Proteolytic Pathways in Thrombus Resolution
    Toni M Antalis; Fiscal Year: 2013
    ..Current therapies rely on anticoagulants to treat DVT, which do not resolve existing blood clots, but only prevent further clot development...
  4. Transfusion Trigger Trial in Coronary Artery Disease: A Pilot Study
    JEFFREY LEE CARSON; Fiscal Year: 2010
    ..frequently become anemic because they undergo invasive procedures and are treated with multiple classes of anticoagulants. Oxygen delivery to the myocardium is flow dependent and myocardial ischemia may be precipitated by low ..
  5. A novel transgenic silkworm system for recombinant glycoprotein production
    Donald L Jarvis; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Many biomedically significant proteins, including antibodies, cytokines, anticoagulants, blood clotting factors, and others are glycoproteins...
  6. New Pathways in Thrombosis and Inflammation Mediated by Semaphorin-Plexin Signali
    Guy A Zimmerman; Fiscal Year: 2010
    ..antithrombotic therapies including cyclooxygenase inhibitors (aspirin), thienopyridines (clopidogrel), and anticoagulants (heparin, warfarin)...
  7. Novel Biomarkers Predictive of Heparin-Induced Thrombocytopenia
    Barbara A Konkle; Fiscal Year: 2010
    ..While alternative anticoagulants are available, they are associated with increased risks of bleeding and increased costs, and have not replaced ..
  8. Recombinant and Chemo-/Bio-Orthogonal Synthesis of Liposomal Thrombomodulin
    Xue Long Sun; Fiscal Year: 2013
    ..Currently available anticoagulants share the common property of disrupting normal hemostatic pathways...
  9. Novel Anti-infective and Anti-thrombotic Micro-patterned Central Venous Catheter
    SHRAVANTHI REDDY; Fiscal Year: 2012
    ..Unlike impregnation of the CVC surface with antimicrobial agents or coating with anticoagulants that have severe limitations in addressing CRBSI and CRT, a next-generation solution that incorporates the non-..
  10. MOLECULAR BASIS OF BLOOD COAGULATION REGULATION
    Steven T Olson; Fiscal Year: 2013
    ..Novel anticoagulant drugs which target serpins and upregulate their normal downregulated function could greatly improve upon currently available anticoagulant drugs which lack specificity and are beset by risks of bleeding . ..
  11. Mechanism of aPL antibody-induced Pregnancy loss
    Jane E Salmon; Fiscal Year: 2010
    ..prevents complement activation and protects mice from pregnancy complications induced by aPL antibodies, while anticoagulants that do not inhibit complement do not protect pregnancies...
  12. 2012 New Insights into Coagulation
    Eleanor Pollak; Fiscal Year: 2012
    ..This year our topic is new oral anticoagulants. We are pleased to have guest speaker Thomas L. Ortel, MD/PhD from Duke University Medical Center. Dr...
  13. Model of Platelet Adhesion and Thrombus Formation
    Michael R King; Fiscal Year: 2013
    ..The simulation will be first applied to the clinical investigation and diagnosis of hereditary bleeding disorders, and in the future will enable phenotype prediction of patients treated with anticoagulants such as aspirin and Plavix.
  14. Effect of Statins and Modifiable Factors on Stroke Outcome in Atrial Fibrillation
    Elaine Hylek; Fiscal Year: 2012
    ..Aspirin is a marginally effective therapy in AF and causes bleeding almost as frequently as anticoagulants, particularly in the elderly...
  15. Antithrombotic Aptamers and Antidotes
    BRUCE ALAN SULLENGER; Fiscal Year: 2013
    ..We believe the generation of such antidote controllable therapeutic agents will lead to safer treatment of a number of cardiovascular disorders and improve the overall health and welfare of the public. ..
  16. CHEMISTRY AND BIOLOGY OF HEPARAN SULFATE
    UMESH RAMANLAL DESAI; Fiscal Year: 2013
    ..specific GAG activators of heparin cofactor II;and developing selected GAGs as clinically useful anticoagulants;Project III (PL: K. Rajarathnam;Co- Investigators: R. Garofalo and J...
  17. The Activation of Prothrombin
    Kenneth G Mann; Fiscal Year: 2011
    ..The systems developed will be utilized to evaluate the influence of anticoagulants and antiplatelet agents on the coagulation response...
  18. Vitamin K Oxidoreductase: function and physiology
    KATHLEEN LUCILE BERKNER; Fiscal Year: 2012
    ..studies will provide fundamental contributions to our understanding of VKOR physiology in VKD protein carboxylation that will lead to the development of superior anticoagulants and improved production of VKD proteins for therapeutic use.
  19. Risks of Warfarin for Elders with Atrial Fibrillation
    Margaret C Fang; Fiscal Year: 2010
    ..risk factors for stroke and hemorrhage associated with atrial fibrillation, identify the optimal use of anticoagulants to prevent atrial Fibrillation-related stroke, direct attention towards social and behavioral barriers to ..
  20. Predictive optimal anticlotting treatment for segmented patient populations
    Peter J Tonellato; Fiscal Year: 2013
    ..transient ischemic attack (TIA, ~5-10%) and are typically managed by the use of anticlotting drugs including anticoagulants (e.g., warfarin and dabigatran) and antiplatelets (e.g., clopidogrel)...
  21. Therapeutic factor XI blockade for sepsis
    ERIK IAN TUCKER; Fiscal Year: 2013
    ..Since no comparable product exists, AXIMAB 14E11 would compete successfully with APC and other anticoagulants under development, including activated FXI inhibitors, and therefore has a very large market potential...
  22. Determinants of fall-related bleeding among older adults with atrial fibrillation
    John A Dodson; Fiscal Year: 2013
    ..in older adults, there is strong evidence that a considerable portion of these individuals are not prescribed anticoagulants. Clinicians repeatedly have cited concerns over fall risk and the sequelae of fall-related major bleeding as a ..
  23. Novel antithrombotic agents to prevent hemodialysis vascular access failure
    TZE CHEIN WUN; Fiscal Year: 2013
    ..Results from this study will also provide critical data for IND filing and further clinical development. ..
  24. The Thrombin-Thrombomodulin Interaction
    Elizabeth A Komives; Fiscal Year: 2012
    ..This discovery has important implications for the development of better anticoagulants and for understanding the potential of TM fragments in the treatment of disseminated intravascular coagulation...
  25. Structure and Function of the Gamma Carboxylase
    KATHLEEN LUCILE BERKNER; Fiscal Year: 2013
    ..new fundamental information important for the development of mechanism-based inhibitors that lead to superior anticoagulants, and will also be significant for the production of therapeutic VKD proteins for applications in hemophilia, ..
  26. Novel Targets in Thrombosis and Atherosclerosis
    Daniel A Lawrence; Fiscal Year: 2012
    ..balance in coronary transplant vasculopathy;and project 4- Identify thrombosis modifier genes and novel anticoagulants In zebrafish...
  27. Thromboregulatory strategies to prolong xenograft survival.
    Simon Robson; Fiscal Year: 2009
    ..An example of this would be the failure of natural porcine anticoagulants, such as thrombomodulin, to interact with human/primate coagulation factors, such as thrombin and Protein C...
  28. COAGULATION ACTIVATION IN SICKLE CELL DISEASE
    Kenneth I Ataga; Fiscal Year: 2010
    ..While the majority of clinical studies using anticoagulants have shown no convincing benefit in the prevention or treatment of acute pain episodes, most of these studies ..
  29. Atrial Fibrillation Precursors May Be Novel Stroke Risk Factors
    Hooman Kamel; Fiscal Year: 2013
    ..abstract_text> ..
  30. Toward a Repertoire of Genetic Models for Coagulation Signaling in Chronic Inflam
    Wolfram Ruf; Fiscal Year: 2010
    ..A comprehensive repertoire of genetic models for coagulation protease signaling will enable testing of innovative therapeutic strategies to interrupt diverse disease processes that are fueled by chronic inflammation. ..
  31. Nanotechnology for One Step Concentration and Preservation of Labile Biomarkers i
    LANCE ALLEN LIOTTA; Fiscal Year: 2010
    ..combine this "smart" nanoparticle technology with standard blood collection tubes, with or without additives/anticoagulants, to rapidly encapsulate cancer biomarkers known to be very rare and labile...
  32. Technology Diffusion, Health Outcomes, and Healthcare Expenditures
    Jonathan S Skinner; Fiscal Year: 2013
    ..the rapid growth in implantable cardioverter defibrillators (ICDs), and the growth in new and expensive anticoagulants - dabigatran, apixaban and rivaroxaban...
  33. Field Triage of Head Injured Older Adults Taking Anticoagulants or Platelet Inhib
    DANIEL KIDEN NISHIJIMA; Fiscal Year: 2013
    ....
  34. Delivery of Anti-thrombotic Drugs by Blood Cells
    Vladimir R Muzykantov; Fiscal Year: 2012
    ..Prevention by anticoagulants and anti-platelet agents and therapeutic thrombolysis by fibrinolytic plasminogen activators, PA have limited ..
  35. NIH Phase II-UNCD as Bio-Inert Interface for Anti-Thrombogenicity Applications in
    Hongjun Zeng; Fiscal Year: 2013
    ..In addition, most pregnant and immune compromised patients cannot normally take anticoagulants. Advanced Diamond Technologies (ADT) proposes to eliminate thrombus without the help of anticoagulants, by ..
  36. Garlic Metabolism and Cytochrome P450 Modulation
    Danny Shen; Fiscal Year: 2007
    ..Adverse interactions between garlic supplements and several narrow therapeutic drugs, including anticoagulants (warfarin, fuindione) and HIV protease inhibitors (saquinavir, ritonavir), have been reported within the past ..
  37. Venous thromboembolism among California cancer patients
    Helen Chew; Fiscal Year: 2003
    ..This information is important because there is preliminary data suggesting that use of anticoagulants, such as warfarin or low molecular weight heparin, may be beneficial in the primary prevention of VTE among ..
  38. Molecular Biology of Stroke in Humans
    Frank R Sharp; Fiscal Year: 2013
    ..These findings are important since they affect what treatment is used - anticoagulants like coumadin for cardioembolic causes, vascular procedures and anti-platelet agents for large vessel ..
  39. Risk Factors for Venous Thromboembolism in Cancer Patients Receiving Chemotherapy
    Alok A Khorana; Fiscal Year: 2010
    ....
  40. Field Triage of Older Adults Who Experience Traumatic Brain Injury
    Manish N Shah; Fiscal Year: 2013
    ..frequentl sustain TBIs after low-mechanism injuries, such as falls from standing height, and frequently use anticoagulants and platelet inhibitors, which place them at risk for worse clinical outcomes...
  41. SYNTHESIS AND TESTING OF A NEW CLASS OF HEPARINOIDS
    Joseph Toce; Fiscal Year: 1991
    ..During a literature search, the applicant found that sulphonated bis-lactobionic acid amines are potential anticoagulants. In heparin, the 3-0'-sulphate on the middle sugar is essential for anticoagulant activity...
  42. Improving Patient Safety by Reducing Medication Errors
    BRIAN STROM; Fiscal Year: 2005
    ..The elderly are particularly at risk for such complications. The highest risk drugs include anticoagulants, anticonvulsants, antimicrobials, and digoxin...
  43. FACTOR VA INTERACTIONS REGULATING PROTHROMBIN ACTIVATION
    Paul E Bock; Fiscal Year: 2010
    ..substrate specificity of coagulation proteinases will facilitate the development of novel exosite-directed anticoagulants. Relevance...
  44. Preventing Gastroduodenal Bleeding in Oral Anticoagulant Users
    Wayne A Ray; Fiscal Year: 2013
    ..Novel oral anticoagulants, more convenient to use than warfarin, will account for a growing proportion of oral anticoagulant use...
  45. Clinical and Genetic Predictors of Unstable Warfarin Response
    BRIAN FINKELMAN; Fiscal Year: 2013
    ....
  46. Contribution of Structural Motifs to Heparin Clearance
    ELIZABETH PEMPE; Fiscal Year: 2012
    ..From these studies, we hope to elucidate the specific carbohydrate structures that control heparin clearance, which will be a powerful tool in creating anticoagulant drugs that are tailored to specific applications and patients. ..
  47. Novel Recombinant Anticoagulant Proteins
    TZE CHEIN WUN; Fiscal Year: 2005
    ..Currently available anticoagulant drugs have various limitations. More efficacious, safer, and easier to use anticoagulants are demanded...
  48. Development of an antidote-controlled FIXa inhibitor
    Christopher Rusconi; Fiscal Year: 2004
    ..Thus, there is a critical need for safer anticoagulants, particularly agents whose activity can be readily controlled, to reduce the number and magnitude of such ..
  49. Pharmacologic treatment of thromboembolism
    TZE CHEIN WUN; Fiscal Year: 2009
    ..b>Anticoagulants are pivotal agents in the prevention and treatment of arterial and venous thrombosis...
  50. REGULATION OF INDUCIBLE GENE EXPRESSION IN MONOCYTES
    Nigel Mackman; Fiscal Year: 2009
    ..Recent studies indicate that administration of anticoagulants or anti-inflammatory agents reduces mortality in animal models of endotoxemia and sepsis...
  51. THERAPY WITH ANNEXINS FOR ANTIPHOSPHOLIPID SYNDROME
    MARIA BEGONA CAMPOS NACIFF; Fiscal Year: 2004
    ..Therefore, our initial hypothesis is that annexins could act in vivo as potent anticoagulants and could be beneficial in treating APS...
  52. Novel Reagents to Bypass Limitations of Existing Coagulation Assays
    Stephen Burgess; Fiscal Year: 2009
    ..develop a coagulation assay that is reproducible, reliable and that can be used for patients presenting Lupus anticoagulants. We have introduced and started to study a novel PS compound containing two saturated chains of only six ..
  53. Mechanisms of aPL antibody-induced pregnancy loss
    Jane Salmon; Fiscal Year: 2005
    ..prevents complement activation and protects mice from pregnancy complications induced by aPL antibodies, while anticoagulants that do not inhibit complement do not protect pregnancies...
  54. Antithrombotic Activity of Ascidian Glycosaminoglycans
    DOUGLAS TOLLEFSEN; Fiscal Year: 2004
    ..will provide insight into the antithrombotic mechanisms of glycosaminoglycans and may lead to development of anticoagulants with fewer side effects, improved pharmacokinetics, or greater potency than standard heparin preparations...
  55. Optimizing Cardiovascular Device Thromboresistance for Eliminating Anticoagulants
    Danny Bluestein; Fiscal Year: 2013
    ..The technology offered will become an essential tool for manufacturers that seek to create, redesign and test a cardiovascular device. ..
  56. Bioprocessing of Plasma Therapeutic Proteins using Sequential Affinity Monolithic
    Yow Pin Lim; Fiscal Year: 2007
    ..of highly purified therapeutic plasma derivatives that includes coagulation factors, protease inhibitors and anticoagulants. Nevertheless, the scarcity of human plasma has created a pressing need for improving the yield of purified ..
  57. DEVELOPMENT OF NOVEL THERAPEUTICS FOR ATHEROSCLEROSIS
    KIRK MAPLES; Fiscal Year: 2000
    ..g., aspirin and anticoagulants). Any therapeutic that could limit atherosclerotic damage would have widespread medical and commercial appeal...
  58. A Novel Family of Anticoagulants from Ixodes scapularis
    Michel Ledizet; Fiscal Year: 2003
    ..This tick's saliva contains potent anticoagulants, including a Factor Xa inhibitor...
  59. Complex Antithrombotic Therapy in Older Veterans: GI Risk and Preference
    Neena S Abraham; Fiscal Year: 2012
    Project Background: Drugs such as anticoagulants and antiplatelets are commonly prescribed in combination to older veterans for secondary cardioprophylaxis...
  60. Direct Cellular Effects of Blood Coagulation Proteases
    LAURENT MOSNIER; Fiscal Year: 2007
    ..the proposed studies are clear from the large clinical trials, where activated protein C (ARC), but not other anticoagulants reduced mortality in severe sepsis patients and implied that the unique combination of APC's ..
  61. Direct Cellular Effects of Blood Coagulation Proteases
    LAURENT OLIVIER MOSNIER; Fiscal Year: 2010
    ..the proposed studies are clear from the large clinical trials, where activated protein C (ARC), but not other anticoagulants reduced mortality in severe sepsis patients and implied that the unique combination of APC's ..
  62. IMPROVED BINDING OF ANTITHROMBOGENIC AGENTS TO POLYMERS
    RICHARD WHITBOURNE; Fiscal Year: 1992
    ..This promotes localized inhibition of platelet activation and inhibition of fibrin formation...
  63. IMPROVED SURGICAL ANTICOAGULATION USING A HCII AGONIST
    ALAN CARDIN; Fiscal Year: 2001
    ..These anticoagulants, although approved for HIT, are neither optimally safe or effective in CPB and this patient population most ..
  64. STRUCTURE/FUNCTION STUDIES OF ANTIHEMOSTATIC LIPOCALINS
    WILLIAM MONTFORT; Fiscal Year: 2003
    ..These include vasodilators, platelet aggregation inhibitors, and anticoagulants. Most of these substances are proteinaceous, and a number of their targets have been identified...